Iovance Biotherapeutics (BIT:1IOVA) Price Target Decreased by 13.64% to 7.25

Iovance Biotherapeutics (BIT:1IOVA) has experienced a 13.64% reduction in its average one-year price target to €7.25 per share, though this still implies a substantial 303.56% upside from its current €1.80 closing price. Institutional sentiment appears mixed, with a 10.60% decrease in the number of reporting funds and an 11.38% reduction in total institutional shares owned. However, the average portfolio weight dedicated to 1IOVA increased by 39.89%, suggesting higher conviction among remaining investors. Notably, Millennium Management significantly increased its stake, while other major holders like Mhr Fund Management and VTSMX decreased their relative portfolio allocation to the company.

Analysis

The average one-year price target for Iovance Biotherapeutics (BIT:1IOVA) has been revised downwards by 13.64% to €7.25 per share from a prior estimate of €8.39. Despite this reduction, the current target still implies a significant 303.56% upside from the latest closing price of €1.80, with analyst targets ranging widely from €0.79 to €16.40.

Institutional sentiment appears mixed, with a 10.60% decrease in the number of funds reporting positions (down 53 owners) and an 11.38% reduction in total institutional shares owned (to 247,900K shares) over the last quarter. Conversely, the average portfolio weight of funds dedicated to 1IOVA increased by 39.89%, suggesting higher conviction among the remaining or newly allocated institutional investors.

Major institutional holders exhibited divergent strategies: Millennium Management significantly increased its stake by 98.30% in shares and its portfolio allocation by 2,661.74%. In contrast, Mhr Fund Management, Long Focus Capital Management, VTSMX, and Invenomic Capital Management, while increasing their absolute shareholdings, notably decreased their portfolio allocation to 1IOVA by 43.45%, 25.19%, 44.26%, and 12.29% respectively, indicating a relative reduction in conviction.

Key Decisions for Investors

• Investors should evaluate the substantial implied upside from the average price target against the recent 13.64% analyst downgrade.
• Monitor institutional positioning for further shifts, noting the decrease in overall institutional ownership alongside an increase in average portfolio weight among remaining holders, which suggests a bifurcated view.
• Consider the divergent strategies of major institutional investors, particularly Millennium Management's significant increase in allocation versus other large holders reducing their relative exposure, as this indicates varied conviction levels.